Nearly 4 million patients with chronic obstructive pulmonary disease (COPD) or asthma die each year, mostly from severe acute exacerbations.1 For the past 60 years, systemic corticosteroids have been ...
Verona's approval of ensifentrine in COPD offers promising potential with its MoA and safety profile in a competitive market.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback